Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View PBSV insider activity ↗

PBSVPharma-Bio Serv, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$100.46K net loss for the year ended October 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$9MYear ended October 31, 2025
Profit or loss-$100.46KYear ended October 31, 2025
Cash from the business-$214.89KYear ended October 31, 2025
Total assets$11.44MAs of July 31, 2026
Total liabilities$994.74KAs of July 31, 2026
Cash & equivalents$2.87MAs of July 31, 2023
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$17.8M
2018-10
$19.51M
2019-10
$21.56M
2020-10
$20.12M
2021-10
$19.4M
2022-10
$16.98M
2023-10
$9.51M
2024-10
$9M
2025-10

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
November 1, 2024 – October 31, 2025$9,001,096January 29, 202610-K ↗
November 1, 2023 – October 31, 2024$9,509,279January 29, 202610-K ↗
November 1, 2022 – October 31, 2023$16,976,856January 29, 202510-K ↗
November 1, 2021 – October 31, 2022$19,398,727January 29, 202410-K ↗
November 1, 2020 – October 31, 2021$20,115,175January 30, 202310-K ↗
November 1, 2019 – October 31, 2020$21,564,360February 11, 202210-K ↗
November 1, 2018 – October 31, 2019$19,506,911February 1, 202110-K ↗
November 1, 2017 – October 31, 2018$17,797,425January 29, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 15, 2026

Response SHA-256: bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.